BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90. [PMID: 14699490 DOI: 10.1053/j.gastro.2003.10.050] [Cited by in Crossref: 304] [Cited by in F6Publishing: 269] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, Spiegel BMR. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis. Am J Gastroenterol 2006;101:2076-89. [DOI: 10.1111/j.1572-0241.2006.00769.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
2 Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006;13:250-255. [PMID: 16611191 DOI: 10.1111/j.1365-2893.2005.00687.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
3 Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005;81:349-351. [PMID: 15914368 DOI: 10.1532/ijh97.a10411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
4 Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. J Med Virol 2009;81:798-806. [DOI: 10.1002/jmv.21348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
6 Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol. 2007;22:2130-2134. [PMID: 18031370 DOI: 10.1111/j.1440-1746.2006.04609.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
7 Lok ASF. Liver transplantation for patients with lamivudine-resistant HBV: What is the optimal prophylactic strategy? Liver Transpl 2005;11:490-3. [DOI: 10.1002/lt.20409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19:268-274. [PMID: 23447403 DOI: 10.1002/lt.23600] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
10 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
11 Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, Akarca U. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci. 2007;52:3444-3447. [PMID: 17431777 DOI: 10.1007/s10620-006-9718-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
12 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
13 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
14 Sherman M. Personal view: the management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006;23:857-69. [DOI: 10.1111/j.1365-2036.2006.02840.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
15 Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88. [PMID: 17244247 DOI: 10.1111/j.1365-2893.2006.00808.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
16 Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005;11:716-32. [DOI: 10.1002/lt.20492] [Cited by in Crossref: 127] [Cited by in F6Publishing: 104] [Article Influence: 7.5] [Reference Citation Analysis]
17 Cho Y, Lee DH, Chung KH, Jin E, Lee J, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon J, Lee H, Kim CY, Kim YJ. The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Dig Dis Sci 2013;58:1363-70. [DOI: 10.1007/s10620-012-2480-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Peng XM, Gu L, Huang YS, Ma HH, Xie QF, Li G, Gao ZL. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR. J Virol Methods 2005;128:168-75. [PMID: 15950294 DOI: 10.1016/j.jviromet.2005.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
19 Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMID: 21324130 DOI: 10.1186/1743-422x-8-72] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
20 Buti M. Tratamiento de la hepatitis crónica B HBeAg negativo. Gastroenterología y Hepatología 2006;29:50-3. [DOI: 10.1157/13097578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007;27:1185-93. [PMID: 17919229 DOI: 10.1111/j.1478-3231.2007.01580.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
22 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
23 Sheen E, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Nguyen MH. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir: Entecavir for adefovir partial responders. Alimentary Pharmacology & Therapeutics 2011;34:767-74. [DOI: 10.1111/j.1365-2036.2011.04785.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
24 Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol. 2006;81:969-972. [PMID: 16937392 DOI: 10.1002/ajh.20737] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
25 Perrillo R. Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner. J Am Acad Nurse Pract 2006;18:203-15. [PMID: 16681707 DOI: 10.1111/j.1745-7599.2006.00124.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-41. [DOI: 10.1111/j.1365-2036.2006.02855.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
27 Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794-803. [PMID: 18086120 DOI: 10.1111/j.1440-1746.2007.05240.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
28 van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421-1425. [PMID: 15565615 DOI: 10.1002/hep.20464] [Cited by in Crossref: 270] [Cited by in F6Publishing: 244] [Article Influence: 15.0] [Reference Citation Analysis]
29 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
30 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
31 Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983-989. [PMID: 16627542 DOI: 10.1136/ard.2005.043257] [Cited by in Crossref: 150] [Cited by in F6Publishing: 123] [Article Influence: 9.4] [Reference Citation Analysis]
32 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
33 Park MS, Kim BK, Kim KS, Kim JK, Kim SU, Park JY, Kim do Y, Baartarkhuu O, Han KH, Chon CY. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. Clin Mol Hepatol. 2013;19:29-35. [PMID: 23593607 DOI: 10.3350/cmh.2013.19.1.29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
34 Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 2005;43:920-3. [PMID: 16246449 DOI: 10.1016/j.jhep.2005.09.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
35 Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Arase Y, Ikeda K, Kumada H. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007;42:368-74. [PMID: 17530361 DOI: 10.1007/s00535-007-2008-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
36 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
37 Asselah T, Castelnau C, Marcellin P. Traitement de l’hépatite chronique B. La Presse Médicale 2006;35:327-34. [DOI: 10.1016/s0755-4982(06)74578-x] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
38 Dienstag JL. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. Journal of Hepatology 2005;42:158-62. [DOI: 10.1016/j.jhep.2004.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
39 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014;20:401-13. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Reference Citation Analysis]
40 Durantel D, Brunelle MN, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol. 2005;34 Suppl 1:S34-S43. [PMID: 16461221 DOI: 10.1016/s1386-6532(05)80008-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
41 Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010;51:405-14. [PMID: 19839061 DOI: 10.1002/hep.23310] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
42 Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391-1398. [PMID: 15915463 DOI: 10.1002/hep.20723] [Cited by in Crossref: 201] [Cited by in F6Publishing: 185] [Article Influence: 11.8] [Reference Citation Analysis]
43 van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318-325. [PMID: 16871563 DOI: 10.1002/hep.21253] [Cited by in Crossref: 208] [Cited by in F6Publishing: 185] [Article Influence: 13.0] [Reference Citation Analysis]
44 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73. [PMID: 17988233 DOI: 10.1111/j.1365-2036.2007.03567.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
45 Xu X, Tu Z, Wang B, Ling Q, Zhang L, Zhou L, Jiang G, Wu J, Zheng S. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int. 2011;31:1477-1484. [PMID: 21745275 DOI: 10.1111/j.1478-3231.2011.02500.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
46 Leung N. Lamivudine for chronic hepatitis B. Expert Rev Anti Infect Ther. 2004;2:173-180. [PMID: 15482184 DOI: 10.1586/14787210.2.2.173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
47 Micco L, Fiorino S, Loggi E, Lorenzini S, Vitale G, Cursaro C, Riili A, Bernardi M, Andreone P. Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. BMJ Case Rep. 2009;2009:bcr06.2008.0287. [PMID: 21686872 DOI: 10.1136/bcr.06.2008.0287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Leemans WF, Ter Borg MJ, de Man RA. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007;26 Suppl 2:171-82. [PMID: 18081660 DOI: 10.1111/j.1365-2036.2007.03481.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
49 Sun M, Tan G, Song J, Wang J, Wu X. Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2016;40:590-6. [PMID: 27016894 DOI: 10.1016/j.clinre.2016.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Haché C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006;7:1835-1843. [PMID: 16925509 DOI: 10.1517/14656566.7.13.1835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
51 Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci. 2005;20:821-828. [PMID: 16224157 DOI: 10.3346/jkms.2005.20.5.821] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
52 Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE. Management of chronic hepatitis B in the liver transplant setting. Transplantation Reviews 2004;18:171-82. [DOI: 10.1016/j.trre.2004.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
54 Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2011;17:261-267. [PMID: 22310790 DOI: 10.3350/kjhep.2011.17.4.261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
55 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
56 Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. Korean J Hepatol 2008;14:503-12. [PMID: 19119245 DOI: 10.3350/kjhep.2008.14.4.503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother. 2007;60:341-349. [PMID: 17567633 DOI: 10.1093/jac/dkm187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ohishi W, Chayama K. Current treatment for chronic hepatitis B in Japan. Clin J Gastroenterol 2009;2:325-30. [DOI: 10.1007/s12328-009-0100-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
59 Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 [PMID: 25339803 DOI: 10.3748/wjg.v20.i39.14142] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
60 Yuen M, Lai C. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opinion on Pharmacotherapy 2005;5:2361-7. [DOI: 10.1517/14656566.5.11.2361] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
61 Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y. Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci. 2008;53:2999-3006. [PMID: 18618250 DOI: 10.1007/s10620-008-0384-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
62 Zhang H, Wu M, Zhu X, Li C, Li X, Jin W, Zhang D, Chen H, Liu C, Ding Y, Niu J, Liu J. Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. Antiviral Res 2020;174:104693. [PMID: 31838002 DOI: 10.1016/j.antiviral.2019.104693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Dore GJ, Guan R, Wasim Jafri SM, Sarin SV, Keeffe EB. Management of chronic hepatitis B in challenging patient populations. Liver International 2006;26:38-46. [DOI: 10.1111/j.1478-3231.2006.01375.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
64 Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14:176-182. [PMID: 17305883 DOI: 10.1111/j.1365-2893.2006.00797.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
65 Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25:891-898. [PMID: 17402992 DOI: 10.1111/j.1365-2036.2007.03272.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
66 Liaw Y, Leung N, Guan R, Lau GK, Merican I, Mccaughan G, Gane E, Kao J, Omata M; for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89. [DOI: 10.1111/j.1478-3231.2005.01134.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 14.1] [Reference Citation Analysis]
67 Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B: Long-term outcomes of add-on ADV therapy. Hepatology Research 2012;42:1168-74. [DOI: 10.1111/j.1872-034x.2012.01038.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
68 Müller C. Chronic Hepatitis B and C--current treatment and future therapeutic prospects. Wien Med Wochenschr. 2006;156:391-396. [PMID: 16937041 DOI: 10.1007/s10354-006-0314-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, Pulvirenti A, Franchello A, Colombo M, Salizzoni M, Rizzetto M. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005;11:532-8. [DOI: 10.1002/lt.20393] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
70 Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-70. [DOI: 10.1007/s00535-009-0076-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
71 Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079 [PMID: 17696224 DOI: 10.3748/wjg.v13.i30.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
72 Clercq ED, Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928-40. [DOI: 10.1038/nrd1877] [Cited by in Crossref: 485] [Cited by in F6Publishing: 403] [Article Influence: 28.5] [Reference Citation Analysis]
73 Mahabadi M, Alavian SM, Norouzi M, Keyvani H, Mahmoudi M, Jazayeri SM. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B. Electron Physician 2016;8:2466-74. [PMID: 27504160 DOI: 10.19082/2466] [Reference Citation Analysis]
74 Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151. [PMID: 17400303 DOI: 10.1016/j.antiviral.2007.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
75 Fung SK, Lok AS. Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2004;1:90-97. [PMID: 16265070 DOI: 10.1038/ncpgasthep0056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
76 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(14): 1645-1649 [DOI: 10.11569/wcjd.v13.i14.1645] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
77 Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation. 2008;85:1105-1111. [PMID: 18431229 DOI: 10.1097/tp.0b013e31816a342a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
78 Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int 2011;5:654-63. [PMID: 21484148 DOI: 10.1007/s12072-010-9228-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
79 Negreanu L, Baty G, Dubois F, de Muret A, Bacq Y. Hepatitis B virus reactivation after a resolutive acute hepatitis leading to a diagnosis of T cell lymphoma. Dig Liver Dis 2009;41:e39-41. [PMID: 18819852 DOI: 10.1016/j.dld.2008.06.002] [Reference Citation Analysis]
80 Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers. Clinical Therapeutics 2013;35:68-76. [DOI: 10.1016/j.clinthera.2012.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85. [DOI: 10.1002/lt.20258] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
82 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. [PMID: 20659226 DOI: 10.1111/j.1440-1746.2010.06381.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
83 Sigal SH, Ala A, Ivanov K, Hossain S, Bodian C, Schiano TD, Min AD, Bodenheimer HC, Thung SN. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy. Liver Transpl 2005;11:82-8. [DOI: 10.1002/lt.20328] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
84 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
85 van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, Lee AU. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22:1500-1505. [PMID: 17683493 DOI: 10.1111/j.1440-1746.2007.05093.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
86 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
87 Mihm U, Gärtner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Herrmann E. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 2005;43:217-24. [PMID: 15964093 DOI: 10.1016/j.jhep.2005.02.037] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
88 Roche B, Samuel D. [Prevention and treatment of hepatitis B virus infection after liver transplantation]. Gastroenterol Clin Biol 2005;29:393-404. [PMID: 15864201 DOI: 10.1016/s0399-8320(05)80787-0] [Reference Citation Analysis]
89 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am 2006;20:1-25. [PMID: 16527646 DOI: 10.1016/j.idc.2006.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
91 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
92 Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008;2:244-249. [PMID: 19669311 DOI: 10.1007/s12072-008-9045-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
93 Prada Lobato J, Garrido López S, Catalá Pindado MA, García Pajares F. [The prophylaxis against post-liver-transplant hepatitis B re-infection]. Farm Hosp 2007;31:30-7. [PMID: 17439311 DOI: 10.1016/s1130-6343(07)75708-2] [Reference Citation Analysis]
94 Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005;12:386-392. [PMID: 15985009 DOI: 10.1111/j.1365-2893.2005.00608.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
95 Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol. 2006;5:1. [PMID: 16405720 DOI: 10.1186/1476-5926-5-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
96 Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther. 2004;2:745-760. [PMID: 15482237 DOI: 10.1586/14789072.2.5.745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
97 Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr. 2012;55:648-652. [PMID: 22688509 DOI: 10.1097/mpg.0b013e318262a737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
98 Pei F, Ning JY, You JF, Yang JP, Zheng J. YMDD variants of HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol 2005; 11(18): 2714-2719 [PMID: 15884109 DOI: 10.3748/wjg.v11.i18.2714] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
99 Thibault V. Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology. Future Virology 2006;1:553-65. [DOI: 10.2217/17460794.1.5.553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol 2008; 14(27): 4416-4419 [PMID: 18666338 DOI: 10.3748/wjg.14.4416] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
101 Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005): . Chinese Medical Journal 2007;120:2159-73. [DOI: 10.1097/00029330-200712020-00002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
102 Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K. In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol. 2007;45:3335-3341. [PMID: 17687019 DOI: 10.1128/JCM.00272-07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
103 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
104 Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol. 2008;48:540-547. [PMID: 18279995 DOI: 10.1016/j.jhep.2007.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
105 Wen R, Wang J, Yan M. Effect of Traditional Chinese Medicine Xiangganlong combined with Lamivudine in treatment of active hepatitis: An analysis of 90 cases. Shijie Huaren Xiaohua Zazhi 2005; 13(20): 2509-2513 [DOI: 10.11569/wcjd.v13.i20.2509] [Reference Citation Analysis]
106 Potthoff A, Tillmann HL, Bara C, Deterding K, Pethig K, Meyer S, Haverich A, Böker KHW, Manns MP, Wedemeyer H. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat 2006;13:734-41. [DOI: 10.1111/j.1365-2893.2006.00748.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
107 Ferreira MS, Borges AS. [Advances in the treatment of hepatitis B]. Rev Soc Bras Med Trop 2007;40:451-62. [PMID: 17876470 DOI: 10.1590/s0037-86822007000400016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
108 Kim YJ, Kim BG, Jung JO, Yoon JH, Lee HS. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol 2006;41:240-9. [PMID: 16699858 DOI: 10.1007/s00535-005-1750-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
110 Jung YJ, Kim BG, Kim JS, Kim W, Yoon JH, Lee HS, Yi NJ, Lee KW, Suh KS, Kim YJ. The effect of pretransplantation lamivudine resistance on the prognosis of liver transplant recipients. Transplant Proc 2013;45:231-5. [PMID: 23375306 DOI: 10.1016/j.transproceed.2012.06.078] [Reference Citation Analysis]
111 Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48:728-735. [PMID: 18329126 DOI: 10.1016/j.jhep.2007.12.026] [Cited by in Crossref: 111] [Cited by in F6Publishing: 103] [Article Influence: 7.9] [Reference Citation Analysis]
112 Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13:934-945. [PMID: 20825624 DOI: 10.1111/j.1524-4733.2010.00777.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
113 Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WE 4th, Gerin JL, Tennant BC. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. 2004;63:115-121. [PMID: 15302140 DOI: 10.1016/j.antiviral.2004.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
114 Yang Q, Shi YU, Yang Y, Lou G, Lv F. Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis. Biomed Rep 2015;3:269-75. [PMID: 25798251 DOI: 10.3892/br.2015.415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
115 European Association For The Study Of The Liver. [EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol. 2009;33:539-554. [PMID: 19481389 DOI: 10.1016/j.gcb.2009.03.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
116 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
117 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
118 Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253-1261. [PMID: 17030194 DOI: 10.1053/j.gastro.2006.08.013] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 7.8] [Reference Citation Analysis]
119 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Taltavull TC, Chahri N, Verdura B, Gornals J, Lopez C, Casanova A, Cañas C, Figueras J, Casais LA. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int. 2005;18:879-883. [PMID: 15948869 DOI: 10.1111/j.1432-2277.2005.00125.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
121 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
122 Brunetto MR, Colombatto P, Bonino F. Personalized therapy in chronic viral hepatitis. Mol Aspects Med 2008;29:103-11. [PMID: 18068759 DOI: 10.1016/j.mam.2007.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Eisenbach C, Sauer P, Mehrabi A, Stremmel W, Encke J. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006;20 Suppl 17:111-6. [PMID: 17100710 DOI: 10.1111/j.1399-0012.2006.00609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
124 Kim DY, Kim HJ, Lee CK, Suh JH, Kim DH, Cho YS, Won SY, Park BK, Park IS. Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. Liver Int. 2007;27:47-53. [PMID: 17241380 DOI: 10.1111/j.1478-3231.2006.01407.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
125 Elewa U, Sandri AM, Kim WR, Fervenza FC. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 2011;119:c41-9; discussion c49. [PMID: 21677438 DOI: 10.1159/000324652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
126 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America 2005;89:345-69. [DOI: 10.1016/j.mcna.2004.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
127 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
128 Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006;78:1025-34. [DOI: 10.1002/jmv.20658] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
129 Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol. 2008;80:1160-1170. [PMID: 18461609 DOI: 10.1002/jmv.21206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
130 Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol. 2004;41:362-369. [PMID: 15336437 DOI: 10.1016/j.jhep.2004.06.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
131 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
132 Schildgen O, Schewe CK, Vogel M, Däumer M, Kaiser R, Weitner L, Matz B, Rockstroh JK. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment: . AIDS 2004;18:2325-7. [DOI: 10.1097/00002030-200411190-00014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
133 Suárez E, Gila A, Figueruela B, Chueca N, Muñoz Rueda P, Puche B, Fraga E, García F, Martín JM, Andrade RJ, Nogales C, Romero-Gómez M, Salmerón J. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. Gastroenterol Hepatol 2011;34:69-74. [PMID: 21334762 DOI: 10.1016/j.gastrohep.2010.11.003] [Reference Citation Analysis]
134 Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. J Med Virol 2015;87:999-1007. [PMID: 25711201 DOI: 10.1002/jmv.24150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. J Med Virol 2011;83:953-61. [DOI: 10.1002/jmv.22025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
136 Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY, Chen DS. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. J Viral Hepat 2006;13:387-95. [PMID: 16842441 DOI: 10.1111/j.1365-2893.2005.00704.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
137 Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X, Huang MJ. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11(6): 867-870 [PMID: 15682483 DOI: 10.3748/wjg.v11.i6.867] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
138 Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon α-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom: . European Journal of Gastroenterology & Hepatology 2007;19:631-8. [DOI: 10.1097/meg.0b013e3281108079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
139 Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Clin Mol Hepatol 2016;22:443-9. [PMID: 27880997 DOI: 10.3350/cmh.2016.0037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
140 Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, Varaut A, Morales E, Nalpas B, Brosgart C. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation. 2005;80:1086-1092. [PMID: 16278590 DOI: 10.1097/01.tp.0000178305.39231.a2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
141 Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol 2004;15:313-26. [PMID: 18159509 DOI: 10.1155/2004/326964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
142 Bourlière M, Fontaine H, Yazdanpanah Y, Piroth L, Benhamou Y. Co-infection avec les hépatites virales. J Afr Hepato Gastroenterol 2007;1:38-50. [DOI: 10.1007/s12157-007-0015-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 2007;46:1049-56. [DOI: 10.1002/hep.21783] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
144 Hadziyannis SJ, Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Review of Anti-infective Therapy 2014;2:475-83. [DOI: 10.1586/14787210.2.4.475] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
145 Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 2008;48:923-31. [DOI: 10.1016/j.jhep.2008.02.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
146 Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol 2014;49:1094-104. [DOI: 10.1007/s00535-013-0864-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
147 Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J. 2009;6:163. [PMID: 19818142 DOI: 10.1186/1743-422x-6-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
148 Fung SK, Lok AS. Update on viral hepatitis in 2004. Curr Opin Gastroenterol 2005;21:300-7. [PMID: 15818150 DOI: 10.1097/01.mog.0000158109.13722.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
149 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
150 de Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc. 2006;38:3118-3120. [PMID: 17112914 DOI: 10.1016/j.transproceed.2006.08.186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
151 Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12:333-345. [PMID: 15985003 DOI: 10.1111/j.1365-2893.2005.00599.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
152 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
153 Fung SK, Fontana RJ. Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease 2006;10:275-302. [DOI: 10.1016/j.cld.2006.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
154 Perrillo R, Nair S. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 635-63. [DOI: 10.1016/b978-1-4160-3258-8.50036-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance? Journal of Gastroenterology and Hepatology 2009;24:429-35. [DOI: 10.1111/j.1440-1746.2008.05760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
156 Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2417-2422 [PMID: 16688836 DOI: 10.3748/wjg.v12.i15.2417] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
157 Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012;47:577-85. [PMID: 22231575 DOI: 10.1007/s00535-011-0522-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
158 Santos SA, Uriel AJ, Park JS, Lucas J, Carriero D, Jaffe D, Dieterich DT. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen: . European Journal of Gastroenterology & Hepatology 2006;18:1247-53. [DOI: 10.1097/01.meg.0000243877.17444.5e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
159 Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H. Application of hepatitis B virus replication mouse model. World J Gastroenterol 2010; 16(16): 1979-1985 [PMID: 20419834 DOI: 10.3748/wjg.v16.i16.1979] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
160 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
161 Wang F, Zhang J, Zhang XG, Zhang J, Li DM. Adefovir combined with lamivudine in treatment of lamivudine-resistant patients with decompensated liver cirrhosis: an analysis of 14 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(13): 1468-1470 [DOI: 10.11569/wcjd.v16.i13.1468] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008;28:28-38. [PMID: 17976155 DOI: 10.1111/j.1478-3231.2007.01618.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]
163 Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, Touloumi G, Economou M, Vlachogiannakos J, Spandidos D, Avgerinos A, Tzourmakliotis D. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006;23:787-95. [DOI: 10.1111/j.1365-2036.2006.02806.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
164 Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49:S112-S121. [PMID: 19399795 DOI: 10.1002/hep.22920] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
165 Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14 Suppl 1:37-44. [PMID: 17958641 DOI: 10.1111/j.1365-2893.2007.00916.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
166 Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6:268-274. [PMID: 18328434 DOI: 10.1016/j.cgh.2007.12.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
167 Liaw YF. The current management of HBV drug resistance. J Clin Virol. 2005;34 Suppl 1:S143-S146. [PMID: 16461216 DOI: 10.1016/s1386-6532(05)80025-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
168 Feitelson MA, Clayton MM, Reis HM, Wu G, Lu EP. Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. Expert Opin Pharmacother 2008;9:2233-45. [PMID: 18710349 DOI: 10.1517/14656566.9.13.2233] [Reference Citation Analysis]
169 Zhang XG, Miao J, Li MW, Jiang SP, Hu FQ, Du YZ. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. J Zhejiang Univ Sci B. 2008;9:506-510. [PMID: 18543406 DOI: 10.1631/jzus.b0820047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
170 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 2009;9:S116-30. [DOI: 10.1111/j.1600-6143.2009.02902.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
171 Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006;71:206-215. [PMID: 16716414 DOI: 10.1016/j.antiviral.2006.04.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
172 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-76. [PMID: 19374144 DOI: 10.1177/095632020901900404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
173 Okanoue T, Minami M. Update of research and management of hepatitis B. J Gastroenterol 2006;41:107-18. [PMID: 16568369 DOI: 10.1007/s00535-006-1774-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
174 Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008;15:392-8. [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
175 Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? Hepatology 2006;43:S182-93. [DOI: 10.1002/hep.20970] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
176 Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, Wu YH, Fu RQ. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. Med Sci Monit. 2013;19:751-756. [PMID: 24019010 DOI: 10.12659/msm.889443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
177 Vassiliadis T, Nikolaidis N, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Zezos P, Gkisakis D, Theodoropoulos K, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005;21:531-7. [PMID: 15740536 DOI: 10.1111/j.1365-2036.2005.02388.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
178 Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol 2010;22:736-40. [PMID: 19550344 DOI: 10.1097/MEG.0b013e32832e0a44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Ni Laoi B, Herra C, Norris S, Crowley B. First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland. Journal of Antimicrobial Chemotherapy 2006;57:1009-10. [DOI: 10.1093/jac/dkl065] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P, Lot M, Trepo C, Zoulim F. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol. 2005;42:279-281. [PMID: 15664258 DOI: 10.1016/j.jhep.2004.09.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
181 Hann HW, Dunn SR, Ahn M, Park SY. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). J Med Virol 2010;82:1489-93. [PMID: 20648601 DOI: 10.1002/jmv.21842] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-1451. [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079] [Cited by in Crossref: 230] [Cited by in F6Publishing: 211] [Article Influence: 15.3] [Reference Citation Analysis]
183 Mutimer D. Prevention of de novo hepatitis B virus infections: More seems no better: Editorial. Liver Transpl 2010;16:256-8. [DOI: 10.1002/lt.22026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
184 Neff GW, Nery J, Lau DT, O'Brien CB, Duncan R, Shire NJ, Ruiz P, Nery C, Montalbano M, Muslu H. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother. 2004;38:1999-2004. [PMID: 15507498 DOI: 10.1345/aph.1E280] [Cited by in Crossref: 47] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
185 Sawada T, Kubota K. Liver transplantation for hepatocellular carcinoma. Dig Surg 2007;24:126-30. [PMID: 17446707 DOI: 10.1159/000101900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
186 Hao R, Xiang K, Peng Y, Hou J, Sun J, Li Y, Su M, Yan L, Zhuang H, Li T. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Infection, Genetics and Evolution 2015;33:261-8. [DOI: 10.1016/j.meegid.2015.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
187 Zoulim F, Parvaz P, Marcellin P, Zarski J, Beaugrand M, Benhamou Y, Bailly F, Maynard M, Trepo C, Trylesinski A, Monchecourt F; the VIRESPA study group. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver International 2009;29:420-6. [DOI: 10.1111/j.1478-3231.2008.01867.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
188 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
189 Bárcena R, Del Campo S, Moraleda G, Casanovas T, Prieto M, Buti M, Moreno J, Cuervas V, Fraga E, De la Mata M, Otero A, Delgado M, Loinaz C, Barrios C, Dieguez M, Mas A, Sousa J, Herrero J, Muñoz R, Avilés J, Gonzalez A, Rueda M. Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post–Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. Transplantation Proceedings 2005;37:3960-2. [DOI: 10.1016/j.transproceed.2005.10.061] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
190 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
191 Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006;36:100-13. [PMID: 16472264 DOI: 10.1111/j.1445-5994.2006.01027.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
192 Asselah T, Castelnau C, Boyer N, Ripault M, Marcellin P. Traitement de l’hépatite chronique B. Gastroentérologie Clinique et Biologique 2004;28:1215-27. [DOI: 10.1016/s0399-8320(04)95213-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
193 Kim YJ, Paik SW, Sinn DH, Gwak G, Choi MS, Lee JH, Koh KC, Yoo BC. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance: Adefovir add-on in lamivudine-resistance. Journal of Gastroenterology and Hepatology 2012;27:1454-60. [DOI: 10.1111/j.1440-1746.2011.07050.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Asselah T, Ripault MP, Marcellin P. [Chronic hepatitis B: which patients should be treated and how?]. Gastroenterol Clin Biol 2005;29:374-83. [PMID: 15864198 DOI: 10.1016/s0399-8320(05)80784-5] [Reference Citation Analysis]
195 Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B: . PharmacoEconomics 2007;25:963-77. [DOI: 10.2165/00019053-200725110-00006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
196 Wang C, Yu S, Zhang Y, Zhang M, Lv L, Huang C, Li X, Li J, Zhang Z. Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy. Exp Ther Med 2019;17:2473-84. [PMID: 30906435 DOI: 10.3892/etm.2019.7255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
197 Almeida AM, Ribeiro AQ, Pádua CA, Brandão CM, Andrade EI, Cherchiglia ML, Carmo RA, Acurcio Fde A. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop 2010;43:440-51. [PMID: 20802947 DOI: 10.1590/s0037-86822010000400021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
198 Calvaruso V, Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:219-230. [PMID: 21497740 DOI: 10.1016/j.bpg.2011.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
199 Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis. 2013;17:451-473. [PMID: 23905816 DOI: 10.1016/j.cld.2013.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
200 Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. Eur J Intern Med. 2009;20:478-481. [PMID: 19712848 DOI: 10.1016/j.ejim.2008.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
201 Forton D, Karayiannis P. Established and emerging therapies for the treatment of viral hepatitis. Dig Dis 2006;24:160-73. [PMID: 16699274 DOI: 10.1159/000090319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
202 Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488-1495. [PMID: 16461777 DOI: 10.1136/gut.2005.077099] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 9.9] [Reference Citation Analysis]
203 Chakrabarti S, Mukherjee S. Prevention and treatment of hepatitis virus infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2009;1:e2009017. [PMID: 21415956 DOI: 10.4084/MJHID.2009.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Olsen S, Brown R. Hepatitis B treatment: Lessons for the nephrologist. Kidney International 2006;70:1897-904. [DOI: 10.1038/sj.ki.5001908] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
205 Hutton DW, Brandeau ML. Too much of a good thing? When to stop catch-up vaccination. Med Decis Making 2013;33:920-36. [PMID: 23858015 DOI: 10.1177/0272989X13493142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
206 Sims KA, Woodland AM. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy. 2006;26:1745-1757. [PMID: 17125436 DOI: 10.1592/phco.26.12.1745] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
207 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414-1419. [PMID: 16317671 DOI: 10.1002/hep.20939] [Cited by in Crossref: 202] [Cited by in F6Publishing: 184] [Article Influence: 11.9] [Reference Citation Analysis]
209 Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283-290. [PMID: 16338024 DOI: 10.1016/j.jhep.2005.10.018] [Cited by in Crossref: 247] [Cited by in F6Publishing: 210] [Article Influence: 14.5] [Reference Citation Analysis]
210 Hézode C, Chevaliez S, Bouvier-alias M, Roudot-thoraval F, Brillet R, Zafrani E, Dhumeaux D, Pawlotsky J. Efficacy and safety of adefovir dipivoxil 20mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10mg daily. Journal of Hepatology 2007;46:791-6. [DOI: 10.1016/j.jhep.2007.01.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
211 Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther. 2008;30:317-323. [PMID: 18343270 DOI: 10.1016/j.clinthera.2008.02.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
212 Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51. [PMID: 17040114 DOI: 10.2165/00003495-200666140-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
213 Burton JR, Rosen HR. Diagnosis and Management of Allograft Failure. Clinics in Liver Disease 2006;10:407-35. [DOI: 10.1016/j.cld.2006.05.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
214 Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology. 2004;126:343-347. [PMID: 14699512 DOI: 10.1053/j.gastro.2003.11.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
215 Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 2011;45:900-5. [DOI: 10.1097/mcg.0b013e318224d64f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
216 Heipertz RA Jr, Miller TG, Kelley CM, Delaney WE 4th, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol 2007;81:3068-76. [PMID: 17215289 DOI: 10.1128/JVI.02341-06] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
217 Zheng JN, Zou TT, Zou H, Zhu GQ, Ruan LY, Cheng Z, Van Poucke S, Zheng MH. Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther. 2016;14:979-987. [PMID: 27491868 DOI: 10.1080/14787210.2016.1220831] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
218 Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006;44:507-11. [PMID: 16457904 DOI: 10.1016/j.jhep.2005.12.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
219 Cacoub P, Piroth L. Prise en charge des malades coinfectés VIH-VHC et VIH-VHB. Gastroentérologie Clinique et Biologique 2007;31:887-94. [DOI: 10.1016/s0399-8320(07)73986-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
220 Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106. [PMID: 15017613 DOI: 10.1016/s1542-3565(03)00312-4] [Cited by in Crossref: 153] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
221 Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2006;3:446-458. [PMID: 16883349 DOI: 10.1038/ncpgasthep0550] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
222 Koga H, Ide T, Oho K, Kuwahara R, Hino T, Ogata K, Hisamochi A, Tanaka K, Kumashiro R, Toyonaga A. Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis. Hepatol Res. 2007;37:503-509. [PMID: 17539992 DOI: 10.1111/j.1872-034x.2007.00087.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
223 Buti M. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:32-8. [PMID: 19100229 DOI: 10.1016/s0213-005x(08)76517-0] [Reference Citation Analysis]
224 Hui AY, Sung JJ. Advances in chronic viral hepatitis. Curr Opin Infect Dis. 2005;18:400-406. [PMID: 16148526 DOI: 10.1097/01.qco.0000180163.84271.5e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
225 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
226 Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049. [PMID: 16762627 DOI: 10.1053/j.gastro.2006.04.007] [Cited by in Crossref: 306] [Cited by in F6Publishing: 273] [Article Influence: 19.1] [Reference Citation Analysis]
227 Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Akyuz F, Karaca C, Demir K, Besisik F, Onel D. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. Liver Int. 2015;35:2265-2274. [PMID: 25800974 DOI: 10.1111/liv.12831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
228 Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42:173-179. [PMID: 15664241 DOI: 10.1016/j.jhep.2004.10.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
229 Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009;44:601-7. [PMID: 19387534 DOI: 10.1007/s00535-009-0038-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
230 Lim YS, Suh DJ. Current antiviral therapy for chronic hepatitis B. J Korean Med Sci. 2004;19:489-494. [PMID: 15308835 DOI: 10.3346/jkms.2004.19.4.489] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
231 Honda K, Seike M, Maehara SI, Tahara K, Anai H, Moriuchi A, Muro T. Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis. World J Gastroenterol 2012; 18(20): 2586-2590 [PMID: 22654459 DOI: 10.3748/wjg.v18.i20.2586] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
232 Scott JD, Mcmahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009;11:28-36. [DOI: 10.1007/s11894-009-0005-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
233 Park JH, Jung SW, Park NH, Park BR, Kim MH, Kim CJ, Lee BU, Jeong ID, Kim BG, Bang SJ. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. Clin Ther. 2015;37:1433-1442. [PMID: 25956353 DOI: 10.1016/j.clinthera.2015.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
234 Huskey J, Wiseman AC. Chronic viral hepatitis in kidney transplantation. Nat Rev Nephrol 2011;7:156-65. [PMID: 21283138 DOI: 10.1038/nrneph.2010.192] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
235 Gérolami R, Borentain P, Colson P, Norguet E, Gérolami A, Tamalet C. Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion. Liver Int 2007;27:1417-21. [PMID: 18036104 DOI: 10.1111/j.1478-3231.2007.01541.x] [Reference Citation Analysis]
236 Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf. 2011;10:809-818. [PMID: 21671843 DOI: 10.1517/14740338.2011.593507] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
237 Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Valdes A, Martinez M, Esteban R, Guardia J. Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology. 2004;40:133-139. [PMID: 15239096 DOI: 10.1002/hep.20275] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
238 Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl 2008;14:S1-7. [DOI: 10.1002/lt.21615] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
239 Jang JW, Kim MS, Lee SY, Kim CW, Bae SH, Choi JY, Cha SB, Yoon SK. Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy. J Gastroenterol Hepatol 2007;22:1092-7. [DOI: 10.1111/j.1440-1746.2006.04499.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
240 Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant. 2010;24:207-212. [PMID: 19758269 DOI: 10.1111/j.1399-0012.2009.01090.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
241 Joo MK, Yeon JE, Kim JH, Jung YK, Lee SJ, Kim JH, Yim HJ, Byun KS, Park JJ, Kim JS, Bak YT. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment. Scand J Gastroenterol 2008;43:1514-21. [PMID: 18663665 DOI: 10.1080/00365520802273033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
242 Saab S, Chen PY, Saab CE, Tong MJ. The Management of Hepatitis B in Liver Transplant Recipients. Clin Liver Dis 2016;20:721-36. [PMID: 27742010 DOI: 10.1016/j.cld.2016.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
243 Kimberlin DW. Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1551-1567.e6. [DOI: 10.1016/b978-0-323-40181-4.00295-4] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 Karayiannis P, Thomas HC. Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease? Nat Clin Pract Gastroenterol Hepatol 2005;2:138-9. [PMID: 16265154 DOI: 10.1038/ncpgasthep0118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Liaw Y. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how? Hepatology 2007;45:266-8. [DOI: 10.1002/hep.21546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
246 Heo J, Ahn SH, Kweon YO, Kim BH, Chan HL, Horban A, Wongcharatrawee S, Llamoso C, Lee KS. Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1485-93. [PMID: 25587617 DOI: 10.1111/jgh.12567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
247 Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol 2011; 17(43): 4804-4809 [PMID: 22147982 DOI: 10.3748/wjg.v17.i43.4804] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
248 Yi SH, Yi HM, Fu BS, Xu C, Li MR, Zhang Q, Yang Y, Chen GH. Long-term results of liver transplantation for over 60 years old patients with hepatitis B virus-related end-stage liver disease. Hepatobiliary Pancreat Dis Int 2014;13:501-7. [PMID: 25308360 DOI: 10.1016/s1499-3872(14)60316-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-30. [PMID: 19373086 DOI: 10.1097/MOT.0b013e32832b1f32] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
250 Gao LL, Wang XY, Lin JS, Zhang YH, Li Y. Efficacies of β-L-D4A against hepatitis B virus in 2.2.15 cells. World J Gastroenterol 2008; 14(8): 1263-1267 [PMID: 18300355 DOI: 10.3748/wjg.14.1263] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
251 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
252 Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis. 2011;15:753-764. [PMID: 22032527 DOI: 10.1016/j.cld.2011.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
253 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008;48:1460-1466. [PMID: 18925641 DOI: 10.1002/hep.22524] [Cited by in Crossref: 130] [Cited by in F6Publishing: 104] [Article Influence: 9.3] [Reference Citation Analysis]
254 Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477. [PMID: 16801428 DOI: 10.1128/aac.00138-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
255 Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:35-49. [PMID: 17177578 DOI: 10.2165/00044011-200727010-00003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
256 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
257 Zheng JF, Han DK, Li L, Luo XL, Xiao M, Lu SC, Lv J. Intramuscular hepatitis B immunoglobulin combined with entecavir for long-term prophylaxis of hepatitis B re-infection after liver transplantation. Shijie Huaren Xiaohua Zazhi 2009; 17(7): 716-719 [DOI: 10.11569/wcjd.v17.i7.716] [Reference Citation Analysis]
258 Sasadeusz JJ, Locarnini SL, Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B? Medical Journal of Australia 2007;186:204-6. [DOI: 10.5694/j.1326-5377.2007.tb00863.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
259 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242. [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001] [Cited by in Crossref: 1092] [Cited by in F6Publishing: 1017] [Article Influence: 78.0] [Reference Citation Analysis]
260 Nam SW, Bae SH, Lee SW, Kim YS, Kang SB, Choi JY, Cho SH, Yoon SK, Han JY, Yang JM, Lee YS. Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2008; 14(11): 1781-1784 [PMID: 18350610 DOI: 10.3748/wjg.14.1781] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
261 Oliveira GLAD, Almeida AM, Silva ALD, Brandao CMR, Andrade EIG, Cherchiglia ML, Acurcio FDA. Antivirais incorporados no Brasil para hepatite B cronica: analise de custo-efetividade. Rev Saúde Pública 2013;47:769-80. [DOI: 10.1590/s0034-8910.2013047004529] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
262 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
264 Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-frias F, Schapper M, Bonovas S, Esteban R. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Journal of Hepatology 2007;47:366-72. [DOI: 10.1016/j.jhep.2007.04.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
265 Selabe SG, Song E, Burnett RJ, Mphahlele MJ. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. J Med Virol. 2009;81:996-1001. [PMID: 19382250 DOI: 10.1002/jmv.21479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
266 Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. Korean J Hepatol 2007;13:349-62. [PMID: 17898551 DOI: 10.3350/kjhep.2007.13.3.349] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
267 Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Yano M, Goto H. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol. 2007;79:366-373. [PMID: 17311332 DOI: 10.1002/jmv.20824] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
268 Kim M, Jung SW, Shin JW, Park NH. The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance. Dig Dis Sci 2011;56:1215-21. [DOI: 10.1007/s10620-010-1537-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
269 Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok AS. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol. 2007;5:1454-1461. [PMID: 17977800 DOI: 10.1016/j.cgh.2007.08.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
270 Pais R, Benhamou Y. [Long-term therapy for chronic hepatitis B in HIV co-infected patients]. Gastroenterol Clin Biol 2010;34 Suppl 2:S136-41. [PMID: 21095517 DOI: 10.1016/S0399-8320(10)70033-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
271 Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim S, Yoo WD, Cho SW. Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2008;14:58. [DOI: 10.3350/kjhep.2008.14.1.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]